When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Raynaud phenomenon

Last reviewed: 16 Aug 2025
Last updated: 04 Oct 2024

Summary

Definição

História e exame físico

Principais fatores diagnósticos

  • digit pain/discomfort
  • digital paresthesia
  • pallor of digits
  • red and/or blue discoloration of digits
  • dilated capillaries at nailbeds
  • well-defined discoloration
  • magnification of nailbeds
Detalhes completos

Outros fatores diagnósticos

  • heartburn
  • dysphagia
  • puffy hands
  • tight skin
  • arthralgia
  • photosensitivity
  • oral/nasal ulcers
  • alopecia
  • butterfly rash
  • sclerodactyly
  • telangiectasia
  • pleuritic chest pain
  • digital ulcers
  • digital pits
  • digital tuft resorption
  • gangrene of fingertip/finger
  • raised painful red lesions on finger tips
  • autoamputation
Detalhes completos

Fatores de risco

  • female
  • family history
  • connective tissue disease
  • use of certain drugs
  • vibration injury
  • Buerger disease
  • prolonged cold exposure/frostbite
  • colder climate
  • smoking
  • ischemia
  • migraine
  • glaucoma
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • clinical diagnosis
  • antinuclear antibody
  • CBC
  • erythrocyte sedimentation rate
  • C-reactive protein
  • urinalysis
Detalhes completos

Investigações a serem consideradas

  • capillaroscopy
Detalhes completos

Algoritmo de tratamento

AGUDA

severe secondary RP: critical ischemia with digital ulcers or threatened digital loss

CONTÍNUA

primary or mild secondary RP

Colaboradores

Autores

Janet Pope, MD, MPH, FRCPC
Janet Pope

Professor of Medicine

Division of Rheumatology

Department of Medicine

University of Western Ontario

Schulich School of Medicine and Dentistry

Head

Division of Rheumatology

St. Joseph's Health Care

London

Ontario

Canada

Disclosures

JP has been reimbursed for consulting with several pharmaceutical manufacturers unrelated to Rayaud phenomenon. JP’s institution receives research grants from BMS, Janssen, and Seattle Genetics. She has acted as a consultant for AbbVie, Amgen, AstraZeneca, BI, BMS, Celltrion, EMERALD, Frensenius Kabi, GSK, Janssen, JMP, Lilly, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis, Organon, Pfizer, Sandoz, Samsung, and Viatris. JP is a speaker and advisory board member for AbbVie, Amgen, AstraZeneca, BI, BMS, Frensenius Kabi, GSK, Janssen, JMP, Lilly, Novartis, Organon, Pfizer, Sandoz, UCB, and Viatris. She receives no patents or royalties. JP is an author of a number of references cited in this topic.

Revisores

Elena Schiopu, MD

Professor of Medicine

Rheumatologist

Medical College of Georgia at Augusta University

Charlie Norwood Veterans Affairs Medical Center

Augusta

GA

Declarações

ES declares that she has no competing interests.

Ariane L. Herrick, MD FRCP

Reader in Rheumatology and Consultant Rheumatologist

Musculoskeletal Research Group

University of Manchester

Manchester

UK

Declarações

ALH has been a paid speaker for Actelion; a consultant for Actelion and Pfizer; and an investigator in studies sponsored by Actelion, Mediquest, and United Therapeutics. ALH is an author of a number of references cited in this topic.

Bridget Griffiths, MB ChB, MD, MRCP(UK)

Consultant Rheumatologist

Department of Rheumatology

Freeman Hospital

Newcastle upon Tyne

UK

Disclosures

BG declares that she has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Curtiss P, Svigos K, Schwager Z, et al. Part I: epidemiology, pathophysiology, and clinical considerations of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol. 2024 Feb;90(2):223-34. Abstract

Belch J, Carlizza A, Carpentier PH, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017 Oct;46(6):413-23.Full text  Abstract

Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug;76(8):1327-39.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности